AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34558301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 611
Study 32369830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicator performance assessment
Number of subjects: 3383
Study 32369830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics (gender, number of treating general practitioners, number of comorbidities, number of consultations)
Number of subjects: 3383
Study 34358514 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 3%, 5%, 10%, and 15% Piper guineense oil
Number of subjects: 100
Study 34358514 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 10% and 15% Piper guineense oil
Number of subjects: 100
Study 34935955 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorimetric method
Number of subjects: 0
Study 34935955 — intervention group
Group type: COMPARATOR
Intervention: RP-HPLC method
Number of subjects: 0
Study 34935955 — intervention group
Group type: COMPARATOR
Intervention: TLC-densitometric method
Number of subjects: 0
Study 34468691 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-chosen and immediate goals
Number of subjects: 500
Study 34468691 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 500
Study 35411401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 86
Study 35411401 — intervention group
Group type: COMPARATOR
Intervention: PI
Number of subjects: 86
Study 33829271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg thiamine daily
Number of subjects: 335
Study 33829271 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg thiamine daily
Number of subjects: 335
Study 33829271 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg thiamine daily
Number of subjects: 335
Study 33829271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg thiamine)
Number of subjects: 335
Study 35701386 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 52
Study 35701386 — intervention group
Group type: COMPARATOR
Intervention: Femoral blocks (19 fascia iliaca compartment blocks, 14 femoral nerve blocks)
Number of subjects: 52
Study 33849658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 26
Study 33849658 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + CR
Number of subjects: 26
Study 33849658 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + CR
Number of subjects: 26
Study 33849658 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (waiting period)
Number of subjects: 26
Study 32408253 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (Arginine and Leucine) administered for 10 weeks at a dosage of 0.1 g/kg body mass/day
Number of subjects: 12
Study 32408253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32408253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (placebo + AAs)
Number of subjects: 12
Study 33867108 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR role-play training
Number of subjects: 0
Study 32333512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser combined with intradermal injection of PRP
Number of subjects: 30
Study 32333512 — intervention group
Group type: COMPARATOR
Intervention: Intraderma injection of noncross-linked hyaluronic acid
Number of subjects: 30
Study 35279181 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach combined with direct posterior approach
Number of subjects: 64
Study 35279181 — intervention group
Group type: COMPARATOR
Intervention: Direct anterior approach
Number of subjects: 64
Study 34749717 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout-storytelling intervention
Number of subjects: 306
Study 34749717 — intervention group
Group type: COMPARATOR
Intervention: Stress reduction video (attention control)
Number of subjects: 306
Study 36165508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (50 mg daily, increased to 100 mg/day after 2 weeks)
Number of subjects: 66
Study 36165508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 33899498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg
Number of subjects: 138
Study 33899498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg and metoclopramide 10 mg
Number of subjects: 138
Study 33899498 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (control group)
Number of subjects: 138
Study 32333527 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation with extended criteria donor grafts
Number of subjects: 10
Study 36113693 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise group (HEX)
Number of subjects: 120
Study 36113693 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise group (LEX)
Number of subjects: 120
Study 36113693 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 120
Study 36113693 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HEX, LEX, WL)
Number of subjects: 120
Study 32705528 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for 1 month
Number of subjects: 64
Study 32705528 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group untreated)
Number of subjects: 64
Study 32705528 — intervention group
Group type: COMPARATOR
Intervention: N/A (Non-OSA control group)
Number of subjects: 64
Study 36103251 — intervention group
Group type: EXPERIMENTAL
Intervention: Universidade do Bebê (UBB) intervention consisting of monthly workshops focused on reading aloud and a book-lending library
Number of subjects: 400
Study 36103251 — intervention group
Group type: EXPERIMENTAL
Intervention: Universidade do Bebê (UBB) intervention
Number of subjects: 400
Study 36103251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 33086286 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT and exercise
Number of subjects: 103
Study 33086286 — intervention group
Group type: COMPARATOR
Intervention: ST and exercise
Number of subjects: 103
Study 32100656 — intervention group
Group type: COMPARATOR
Intervention: Non-intervened arm of a randomised controlled trial of pro-vitamin A carotenoid biofortified maize
Number of subjects: 200
Study 32100656 — intervention group
Group type: EXPERIMENTAL
Intervention: Season
Number of subjects: 200
Study 32100656 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall on a market day
Number of subjects: 200
Study 32100656 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted within-to-between-person variance ratios
Number of subjects: 200
Study 36028920 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized KS clinical evaluation tool, palliative care integration, standardized treatment, improved consultative services
Number of subjects: 1102
Study 34602640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.1 mg/kg BW intramuscularly (IM)
Number of subjects: 50
Study 34602640 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone 0.01 mg/kg BW pharmacopuncture at GV20 (GV)
Number of subjects: 50
Study 35157529 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 12
Study 35157529 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study 33184972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal Neurostimulation therapy (HGNS)
Number of subjects: 15
Study 35249338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pyruvate (PYR) supplementation
Number of subjects: 14
Study 35249338 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (PLA)
Number of subjects: 14
Study 34985149 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of living with Charcot neuroarthropathy (CN)
Number of subjects: 14
Study 32199338 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Number of subjects: 62
Study 32199338 — intervention group
Group type: COMPARATOR
Intervention: Traditional wound dressing
Number of subjects: 62
Study 34078635 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) knowledge
Number of subjects: 225
Study 34078635 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude towards EBM
Number of subjects: 225
Study 34078635 — intervention group
Group type: EXPERIMENTAL
Intervention: Good level of EBM practice
Number of subjects: 225
Study 34078635 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with EBM practice
Number of subjects: 225
Study 35939102 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 2% lidocaine in the gallbladder bed after removal of the gallbladder
Number of subjects: 82
Study 35939102 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of 2% lidocaine at the port sites before incision
Number of subjects: 82
Study 34999348 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of recombinant human basic fibroblast growth factor (bFGF) + conventional medication
Number of subjects: 100
Study 34999348 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication
Number of subjects: 100
Study 33427546 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 400-mg
Number of subjects: 64
Study 33427546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32565444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM; 15 mg/kg bodyweight)
Number of subjects: 48
Study 32648390 — intervention group
Group type: EXPERIMENTAL
Intervention: Yin-yang balance penetrating acupuncture combined with rehabilitation training
Number of subjects: 60
Study 32648390 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (Control group)
Number of subjects: 60
Study 33476301 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies to SARS-CoV-2
Number of subjects: 104
Study 33476301 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD-IgG levels
Number of subjects: 104
Study 33476301 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG levels against RBD and nucleocapsid protein
Number of subjects: 104
Study 32844540 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate magnesium (1.0 mmol/L)
Number of subjects: 20
Study 32844540 — intervention group
Group type: COMPARATOR
Intervention: Low dialysate magnesium (0.5 mmol/L)
Number of subjects: 20
Study 33957183 — intervention group
Group type: EXPERIMENTAL
Intervention: FYB201
Number of subjects: 477
Study 33957183 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 477
Study 33957183 — intervention group
Group type: COMPARATOR
Intervention: FYB201 vs Ranibizumab
Number of subjects: 477
Study 33957183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 477
Study 33319628 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐T‐rich vitamin E mixture (two capsules daily for 7 or 14 days)
Number of subjects: 0
Study 33319628 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 0
Study 34418014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 15mg/Kg administered 15-30 minutes pre-surgery
Number of subjects: 60
Study 34418014 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2mcg/kg administered at induction of anaesthesia
Number of subjects: 60
Study 34418014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 60
Study 34418014 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 34418014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 33227004 — intervention group
Group type: EXPERIMENTAL
Intervention: A Germ's Journey educational resources (multicomponent intervention)
Number of subjects: 329
Study 33227004 — intervention group
Group type: EXPERIMENTAL
Intervention: A Germ's Journey song intervention
Number of subjects: 329
Study 33227004 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 1)
Number of subjects: 329
Study 33227004 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 329
Study 35264846 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled velsecorat (1872 µg)
Number of subjects: 73
Study 35264846 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled velsecorat
Number of subjects: 73
Study 35264846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 33098463 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 10
Study 33098463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32762677 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated EMDR-Dialectical Behavioural Therapy (DBT)
Number of subjects: 126
Study 32762677 — intervention group
Group type: COMPARATOR
Intervention: EMDR-only
Number of subjects: 126
Study 33570304 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC via telephone added to usual care
Number of subjects: 105
Study 33570304 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 35841488 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined neck implants
Number of subjects: 58
Study 35841488 — intervention group
Group type: COMPARATOR
Intervention: Rough neck implants
Number of subjects: 58
Study 34313610 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 100
Study 34313610 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 100
Study 32248935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness smartphone-app intervention
Number of subjects: 23
Study 36111476 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed porous titanium alloy cage (3D Cage)
Number of subjects: 66
Study 36111476 — intervention group
Group type: COMPARATOR
Intervention: Poly-ether-ether-ketone cage (PEEK Cage)
Number of subjects: 66
Study 33607327 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 30
Study 33607327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32483076 — intervention group
Group type: EXPERIMENTAL
Intervention: C-loop haptic toric IOL (AcrySof Toric IOL, Group A)
Number of subjects: 62
Study 32483076 — intervention group
Group type: COMPARATOR
Intervention: Plate-haptic toric IOL (AT TORBI 709M, Group B)
Number of subjects: 62
Study 32483076 — intervention group
Group type: EXPERIMENTAL
Intervention: C-loop haptic toric IOL (Group A)
Number of subjects: 62
Study 32483076 — intervention group
Group type: COMPARATOR
Intervention: Plate-haptic toric IOL (Group B)
Number of subjects: 62
Study 34838153 — intervention group
Group type: EXPERIMENTAL
Intervention: BPM-P (parent version)
Number of subjects: 1346
Study 34838153 — intervention group
Group type: EXPERIMENTAL
Intervention: BPM-T (teacher version)
Number of subjects: 1346
Study 34838153 — intervention group
Group type: EXPERIMENTAL
Intervention: BPM-P and BPM-T
Number of subjects: 1346
Study 34838153 — intervention group
Group type: EXPERIMENTAL
Intervention: BPM-P
Number of subjects: 1346
Study 34838153 — intervention group
Group type: EXPERIMENTAL
Intervention: BPM-T
Number of subjects: 1346
Study 32329771 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher circulating progesterone levels
Number of subjects: 15595
Study 32329771 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated progesterone concentrations among women in the lowest quintile of estradiol (<6.30 pg/mL)
Number of subjects: 15595
Study 32329771 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated progesterone concentrations among women in higher quintiles of estradiol (Q2‐Q5; ≥6.30 pg/mL)
Number of subjects: 15595
Study 34128486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing e-cigarettes
Number of subjects: 17
Study 34128486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free e-cigarettes
Number of subjects: 17
Study 34128486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 17
Study 34128486 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (both types)
Number of subjects: 17
Study 34030124 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat condition (35 °C)
Number of subjects: 12
Study 34030124 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and polyunsaturated fat intake 24 hr preexercise
Number of subjects: 12
Study 34030124 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein, carbohydrate, total fat, and polyunsaturated fat intake (8 days)
Number of subjects: 12
Study 34030124 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral condition (21 °C)
Number of subjects: 12
Study 33966678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40, 80, 120, or 160 mg)
Number of subjects: 537
Study 33966678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (combined doses)
Number of subjects: 537
Study 33966678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 537
Study 33966678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 32003538 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with iStent implantation (phaco-iStent)
Number of subjects: 32
Study 32003538 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone (phaco)
Number of subjects: 32
Study 32974732 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone 2.5 mg
Number of subjects: 219
Study 32974732 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone 5 mg
Number of subjects: 219
Study 32974732 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone 10 mg
Number of subjects: 219
Study 32974732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 32974732 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone (all doses)
Number of subjects: 219
Study 32912192 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated decision tool with education for physicians and nursing staff
Number of subjects: 897
Study 32912192 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 897
Study 35615013 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX+MZ+FEN (DMF)
Number of subjects: 0
Study 35615013 — intervention group
Group type: COMPARATOR
Intervention: DEX+MZ (DM)
Number of subjects: 0
Study 32853709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical betamethasone valerate cream applied once a day after radiation
Number of subjects: 150
Study 32853709 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 150
Study 34592049 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioids
Number of subjects: 300
Study 34592049 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about opioid effects
Number of subjects: 300
Study 33024992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg twice per day for at least 6 months)
Number of subjects: 3
Study 33024992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 3
Study 33202066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g
Number of subjects: 62
Study 33202066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g
Number of subjects: 62
Study 33202066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 or 2 g)
Number of subjects: 62
Study 33046026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pain management with skin-to-skin contact, breastfeeding, and live parental lullaby singing
Number of subjects: 0
Study 33046026 — intervention group
Group type: COMPARATOR
Intervention: Standard pain care initiated by health care professionals
Number of subjects: 0
Study 35257962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal 2 mg aflibercept (arm 1)
Number of subjects: 27
Study 35257962 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly intravitreal 2 mg aflibercept (arm 2)
Number of subjects: 27
Study 35257962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 27
Study 32873675 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus person-centred care (PCC) by telephone and a digital platform
Number of subjects: 220
Study 32873675 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 220
Study 33462447 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency neuromodulation targeting the orbitofrontal cortex, personalized to the intrinsic beta–gamma frequency of the reward network, applied chronically over 5 days.
Number of subjects: 0
Study 32755413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 1228
Study 32755413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study 32755413 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception blood pressure levels
Number of subjects: 1228
Study 32755413 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in blood pressure from preconception to early pregnancy
Number of subjects: 1228
Study 36163885 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-Obinutuzumab (Ven-Obi)
Number of subjects: 432
Study 36163885 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil-Obinutuzumab (Clb-Obi)
Number of subjects: 432
Study 33667465 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum high-density lipoprotein (HDL) cholesterol
Number of subjects: 0
Study 33667465 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1 (ApoA1) levels
Number of subjects: 0
Study 33667465 — intervention group
Group type: COMPARATOR
Intervention: ApoE4 alleles
Number of subjects: 0
Study 33667465 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically higher HDL cholesterol levels
Number of subjects: 0
Study 32343081 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐5‐HIIT
Number of subjects: 34
Study 32343081 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐10‐HIIT
Number of subjects: 34
Study 32343081 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study 33978334 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 - Spoken feedback with app visibility
Number of subjects: 0